% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • jetmanbash jetmanbash May 6, 2014 11:06 PM Flag

    Time squeeze for AEGR that may very well cause the need for a shelf offering:

    The amount of expenses are going up in order to build infra-structure. They are also getting squeezed from Sanofi/GENZ and Mr. Beer was able to dodge the piper for one more quarter. As time goes on it will be discovered that the fatty infiltration of the liver, the fatty infiltration of the small intestine, the lower HDL, and the increased amount of oxidized LDL will show this to be an inferior drug. The average dosage being given to patients is between 5 and 10mg at a cost of $235K minimum. All the while you have increased risk for fat soluble vitamin deficiencies, malabsorption syndrome, increased inflammatory modulators.......esp. due to that fatty infiltration of the small intestine, the draconian diet, and the diarrhea. Push the dose and you'll see more diarrhea. Then comes some competition from the PCSK9 inhibitors as someone else noted. If this drug fails someone can not say that they have numerous shots on goal. The stock is worth maybe twice its initial offering price. ZAP3 to come. t

6.40-0.14(-2.14%)Feb 10 4:00 PMEST